Concepedia

CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape

Shili Sun, Hui-Xi Zou, Lin Li, Qi Liu, Ning Ding, Lili Zeng, Hui Li, Shengjun Mao

International Journal of Pharmaceutics · 2019 · 34 citations · 23 references

DOI

Concepts

References

23

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

, , +15

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Marco Ruella, David M. Barrett, Saad S. Kenderian et al. · Journal of Clinical Investigation · 2016 · 555 citations · Full text

, , +16

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Saar Gill, Sarah K. Tasian, Marco Ruella et al. · Blood · 2014 · 491 citations · Full text

, , +17

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

David Taussig · Blood · 2005 · 370 citations · Full text

, , +14

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 352 citations · Full text

, , +16